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ABSTRACT
Melanoma harboring BRAF mutations frequently develop resistance to BRAF 
inhibitors, limiting the impact of treatment. Here, we establish a mechanism of 
resistance and subsequently identified a suitable drug combination to overcome the 
resistance. Single treatment of BRAF mutant melanoma cell lines with vemurafenib 
or dabrafenib (BRAF inhibitors) alone or in combination with trametinib (MEK1/2 
inhibitor) resulted in overexpression of Mcl-1. Overexpression of Mcl-1 in A375 
and SK-MEL-28 by transfection completely blocked BRAF and MEK1/2 inhibitor-
mediated inhibition of cell survival and apoptosis. Melanoma cells resistant to BRAF 
inhibitors showed massive expression of Mcl-1 as compared to respective sensitive 
cell lines. Silencing of Mcl-1 using siRNA completely sensitized resistant melanoma 
cells to growth suppression and induction of apoptosis by BRAF inhibitors. In vivo, 
vemurafenib resistant A375 xenografts implanted in athymic nude mice showed 
substantial tumor growth inhibition when treated with a combination of vemurafenib 
and Mcl-1 inhibitor or siRNA. Immunohistochemistry and western blot analyses 
demonstrated enhanced expression of Mcl-1 and activation of ERK1/2 in vemurafenib-
resistant tumors whereas level of Mcl-1 or p-ERK1/2 was diminished in the tumors 
of mice treated with either of the combination. Biopsied tumors from the patients 
treated with or resistant to BRAF inhibitors revealed overexpression of Mcl-1. These 
results suggest that the combination of BRAF inhibitors with Mcl-1 inhibitor may 
have therapeutic advantage to melanoma patients with acquired resistance to BRAF 
inhibitors alone or in combination with MEK1/2 inhibitors.
INTRODUCTION
Melanoma, a malignant transformation of 
melanocytes accounts for the highest number of skin 
cancer related deaths with a 5-year survival probability 
of less than 5% [1]. BRAF mutation is observed in almost 
60% melanomas [2, 3]. Most common mutation in BRAF 
is a single substitution of valine to glutamic acid at codon 
600 (V600E), accounting for almost 90% BRAF mutations 
in melanoma [3–5]. Selective inhibitors targeting 
BRAFV600E have shown significant clinical activity in the 
patients with late stage metastatic melanoma amongst 
which vemurafenib has been recently approved by 
US-FDA [6–8]. In spite of promising initial response, 
there have been several recent reports of acquired 
resistance within 6–9 months of treatment with BRAF 
inhibitors in most of the patients [8, 9]. Moreover, about 
20–30% patients develop squamous cell carcinoma and 
more develop tumor recurrence limiting vemurafenib 
therapy as well as other BRAF targeted therapies [10, 11]. 
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The ‘acquired resistance’ occurring in the tumors that were 
earlier sensitive to BRAF inhibitor treatment has emerged 
as a major obstacle in the treatment of the patients with 
late stage metastatic melanoma with BRAFV600E mutation 
leading to poor prognosis. Therefore, a combination 
of BRAF inhibitor (dabrafenib) and MEK1/2 inhibitor 
(trametinib) was approved in early 2014 for the treatment 
of metastatic melanoma, to which incidences of resistance 
has already been observed [12, 13]. Hence, identification 
of the mechanism behind the resistance and formulating 
a drug combination to overcome resistance is of prime 
importance.
Myeloid cell leukemia – 1 (Mcl-1) is pro-survival 
member of Bcl-2, which is known to promote oncogenesis 
not through cell proliferation but by inhibition of 
apoptosis, hence leading to immortalization of malignant 
cells [14, 15]. Its expression is regulated by transcription 
factors like STATs, cAMP response elements and NFκB 
[16]. Mcl-1 is frequently overexpressed in a variety 
of human cancers thereby providing protection to the 
tumor cells from apoptosis [17, 18]. Hence, Mcl-1 has 
been identified as an important target in majority of 
human cancers [19, 20] and several therapeutic strategies 
focusing on Mcl-1 inhibition are currently under 
development [21–25].
In this study, we have established that resistance to 
BRAF inhibitors such as vemurafenib or dabrafenib alone 
or in combination with MEK1/2 inhibitor (trametinib) 
in melanoma cells was due to overexpression of Mcl-1. 
Moreover, our results suggest that combination of BRAF 
inhibitors with Mcl-1 targeted therapies were successful 
in overcoming acquired resistance in melanoma in vitro 
and in vivo.
RESULTS
Vemurafenib treatment induces Mcl-1 expression 
in melanoma cells
To choose the working concentration, we 
initially determined concentration-dependent effects of 
vemurafenib using cell viability assay. We used A375 
and SK-MEL-28 melanoma cells, both of which harbor 
BRAF mutation at V600E. The IC50 of vemurafenib in 
A375 and SK-MEL-28 cells at 72 hours of treatment 
were 0.1 μM and 0.075 μM respectively (Fig. 1A–1B). 
Based on these results, A375 and SK-MEL-28 cells were 
treated with 0.1, 0.2 and 0.4 μM vemurafenib for 72 hours 
(Fig. 1C). Our results showed a significant upregulation of 
Mcl-1 expression upon vemurafenib treatment in both the 
cell lines (Fig. 1C). Vemurafenib treatment increased the 
expression of Mcl-1 by 4.7, 5.2 and 4.5 fold in A375 cells 
and by 10, 11 and 14 fold in SK-MEL-28 cells at 0.1, 0.2 
and 0.4 μM respectively (Fig. 1C). However, there was no 
significant change in the expression of Bcl-2 and Bcl-XL 
upon vemurafenib treatment (Fig. 1C). We further treated 
eight other melanoma cell lines with 0.4 μM vemurafenib 
and observed significant upregulation of Mcl-1 in all 
the cell lines (Supp Fig. 1). The fold increase in Mcl-1 
expression in all the cell lines induced by single treatment 
of vemurafenib is shown in Fig. 1D.
Although the viability of A375 and SK-MEL-28 
cells treated with 0.4 μM vemurafenib (4XIC50) was 
reduced by 60%, a remarkable increase in Mcl-1 
expression was observed (Fig. 1C). These observations 
were intriguing and indicated that the increase in Mcl-1 
expression we observed was perhaps coming from the 
remaining 40% of live attached cells that were resistant to 
vemurafenib. We therefore separated attached and floating 
cells after vemurafenib treatment and compared the levels 
of Mcl-1 by western blotting. Our results showed that 
there was a diminished expression of Mcl-1 in the dead 
floating cells (Figs. 1E–1F). In contrast, cells that survived 
upon vemurafenib treatment had significant upregulation 
of Mcl-1 as compared to control cells indicating that 
expression of Mcl-1 perhaps protected the cells from the 
cytotoxic effects of vemurafenib (Figs. 1E–1F).
Mcl-1 inhibitor enhances the growth suppressive 
effects of vemurafenib
Since we observed that the cells that survived 
after vemurafenib treatment had significant upregulation 
of Mcl-1, we wanted to see whether TW-37, a 
Mcl-1 inhibitor, enhances vemurafenib mediated growth 
suppression. Vemurafenib (0.4 μM) treatment reduced 
the viability of A375 and SK-MEL-28 cells by 48% and 
55% respectively (Figs. 1G–1H). TW-37 alone decreased 
the viability of A375 and SK-MEL-28 cells by 40% and 
58% respectively (Figs. 1G–1H). However, combination 
of vemurafenib and TW-37 treatment reduced the cell 
survival by 85% and 79%, which was significantly higher 
than any of the single treatments (Figs. 1G–1H). These 
observations correlated with our western blot results. 
Vemurafenib failed to stimulate Mcl-1 when co-treated 
with TW-37 (Figs. 1I–1J). The combination treatment 
significantly induced the cleavage of caspase 3 and PARP, 
which was higher than any of the individual treatments, 
indicating apoptosis (Figs. 1I–1J).
Vemurafenib resistant melanoma cells exhibit 
Mcl-1 overexpression
We further wanted to investigate the levels of 
Mcl-1 in the cells with vemurafenib resistance. Hence, we 
generated A375-VR and SK-MEL-28-VR vemurafenib 
resistant cell lines. The IC50 of vemurafenib in A375-VR 
and A375 X/R was 3.0 μM and 2.2 μM respectively, and 
that in SK-MEL-28-VR was 3.3 μM as compared to the 
IC50 of 0.1 μM and 0.075 μM in A375 and SK-MEL-28 
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Figure 1: Vemurafenib treatment induces Mcl-1 expression in melanoma cells. A. A375 and B. SK-MEL-28 cells were treated 
with various concentrations of vemurafenib for 72 hours. Following the treatment, cells were stained with Sulforhodamine B and the 
surviving cells were quantitated spectrophotometrically. The experiment was performed at least three times independently, each time with 
eight replicates and the data expressed as mean ± S.D. C. A375 and SK-MEL-28 cells were treated with 0.1, 0.2 and 0.4 μM vemurafenib 
for 72 hours. Following treatment, cell lysates were subjected to western blotting and analyzed for Mcl-1 expression. Each experiment 
was performed at least three times independently. D. Ten BRAF mutant cell lines were treated with 0.4 μM vemurafenib for 72 hours. The 
protein was collected, subjected to western blotting and analyzed for Mcl-1 expression. Fold increase in Mcl-1 expression was calculated 
by densitometric analysis. Actin was used as a loading control. Each experiment was performed at least three times independently. E. A375 
and F. SK-MEL-28 cells were treated with 0.4 μM vemurafenib for 72 hours. Following the treatment, live cells were separated from 
dead floating cells and the lysates were prepared. The protein was subjected to western blotting and analyzed for Mcl-1 expression. 
Each experiment was performed three times independently. TW-37 enhanced the efficacy of vemurafenib in melanoma cells by inhibition 
of Mcl-1. 
(Continued )
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parent (sensitive) cell lines (Fig. 2A). In all, we achieved 
30–40 fold resistance to vemurafenib in these cell lines. 
The viability of resistant cells was not suppressed at the 
concentrations that suppressed more than 60% growth 
of the sensitive cell lines (Fig. 1G–1H and 2C). As 
expected, western blot results showed a massive increase 
in Mcl-1 expression in vemurafenib resistant cell lines 
(Fig. 2B). The fold increase of Mcl-1 expression in A375-
VR and A375-X/R was 6.2 and 4.8 respectively, and that 
in SK-MEL-28-VR was 10.1, as compared to respective 
sensitive cells (Fig. 2B). Moreover, there was also a 
significant increase in the phosphorylation of ERK1/2 in 
all the resistant cell lines (Fig. 2B). We did not observe 
any significant difference in the expression of Bcl-2 and 
Bcl-XL between the wild type and resistant cell lines 
(Fig. 2B).
Mcl-1 inhibitor overcomes vemurafenib 
resistance in melanoma cells
Vemurafenib, at a concentration of 0.4 μM, 
exhibited negligible effect on the survival of A375-
VR cells (Fig. 2C). The survival of A375-VR cells was 
decreased by 25% when treated with TW-37 (Fig. 2C). 
However, when these resistant cells were treated with 
both TW-37 and vemurafenib, the survival of A375-
VR cells was decreased significantly by 80% (Fig. 2C). 
Similarly, in SK-MEL-28-VR cells, vemurafenib showed 
minimal effect but when combined with TW-37, the 
survival of resistant cells was suppressed by about 80% 
(Fig. 2C). TW-37 treatment alone reduced the growth of 
SK-MEL-28-VR cells by 25% only (Fig. 2C). The enhanced 
efficacy of vemurafenib when combined with TW-37 can 
Figure 1: (Continued ) G. A375 and H. SK-MEL-28 cells were treated with 0.5 μM TW-37 one hour prior to treatment with 0.4 μM 
vemurafenib for 72 h. Cell survival was evaluated spectrophotometrically. The experiment was performed at least three times independently, 
each time with four replicates and the data is expressed as mean ± S.D. *p < 0.05 when compared with control. #, p < 0.05 when compared 
with vemurafenib treatment. In a similar experiment, lysates of I. A375 and J. SK-MEL-28 cells were subjected to western blotting and 
analyzed for Mcl-1, cleaved caspase 3 and cleaved PARP. Each experiment was performed at least three independent times. β actin was 
used as loading control in all the western blot experiments.
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Figure 2: Vemurafenib resistant melanoma cells exhibit Mcl-1 overexpression. A. A375, A-375-VR, SK-MEL-28, SK-MEL-
28-VR and A375X/R cells were treated with various concentrations of vemurafenib for 72 hours following which the cell survival was 
analyzed by sulforhodamine B assay. The experiment was performed at least three times independently, each time with eight replicates and 
the data is expressed as mean ± S.D. B. Lysates of A375, A375-VR, SK-MEL-28, SK-MEL-28-VR and A375X/R were subjected to western 
blotting and analyzed for Mcl-1. Each experiment was performed three times independently. Mcl-1 inhibitor overcomes vemurafenib 
resistance in melanoma cells. C–D. A375-VR, SK-MEL-28-VR and A375X/R cells were treated with 0.5 μM TW-37 one hour prior to the 
treatment with 0.4 μM vemurafenib for 72 h after which cell survival or apoptosis was evaluated. The experiment was performed at least 
three times independently, each time with four replicates and the data expressed as mean ± S.D. *p < 0.05 when compared with control. #, 
p < 0.05 when compared with vemurafenib treatment. E. In a similar experiment, lysates of A375-VR, SK-MEL-28-VR and A375X/R cells 
were subjected to western blotting and analyzed for Mcl-1, p-ERK1/2, ERK1/2, cleaved caspase 3 and cleaved PARP. Each experiment was 
performed at least three independent times. β actin was used as a loading control in all the western blot experiments.
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be attributed to the inhibition of Mcl-1, rendering the cells 
sensitive to vemurafenib. Similar results were observed in 
A375-X/R cells (Fig. 2C). These observations were further 
validated by apoptosis assay. Vemurafenib treatment failed 
to induce apoptosis in all the vemurafenib resistant cell 
lines (Fig. 2D). There was a 2-fold increase in apoptosis 
when these cells were treated with TW-37 (Fig. 2D). 
Finally, when these cells were treated with a combination 
of TW-37 and vemurafenib, there was more than 5-fold 
increase in apoptosis (Fig. 2D). Our western blot results 
showed marked expression of Mcl-1 in vemurafenib 
resistant untreated cells, whereas vemurafenib treatment 
further increased the expression of Mcl-1 in all the resistant 
cell lines and no cleavage of caspase 3 was observed in 
all the cell lines (Fig. 2E). However, vemurafenib in 
combination with TW-37, which significantly inhibited 
Mcl-1, increased the cleavage of caspase 3 and PARP, 
indicating apoptosis (Fig. 2E). Activation of ERK1/2 was 
also observed in vemurafenib resistant cell lines (Fig. 2E). 
Furthermore, vemurafenib treatment did not have any 
effect on phosphorylation of ERK1/2 at Thr202/Tyr204 
but when combined with TW-37, ERK1/2 phosphorylation 
was suppressed (Fig. 2E). No change in the protein level 
of ERK1/2 was observed by individual or combination 
treatment (Fig. 2D). These results clearly indicated the role 
of Mcl-1 in inducing resistance to vemurafenib in malignant 
melanoma cells.
Mcl-1 overexpression reduce the sensitivity of 
melanoma cells to vemurafenib
To further characterize the role of Mcl-1 in 
vemurafenib resistance, we overexpressed Mcl-1 in 
A375 and SK-MEL-28 cells by transfecting the cells with 
Mcl-1 overexpressing plasmid. The survival of A375 cells 
was reduced by about 55% and 75% and SK-MEL-28 
cells by 57% and 67%, when treated with 0.2 μM and 
0.4 μM vemurafenib respectively (Fig. 3A). However, 
upon Mcl-1 overexpression, the effect of vemurafenib 
was significantly reduced in both the cell lines (Fig. 3A). 
For example, the survival of Mcl-1 overexpressing A375 
was reduced merely by 18% and 24% when treated 
with 0.2 μM and 0.4 μM of vemurafenib respectively 
(Fig. 3A). Similarly, SK-MEL-28 cells overexpressing 
Mcl-1 were completely resistant when treated with 
0.2 μM vemurafenib whereas 0.4 μM reduced the 
survival of cells by only 18% (Fig. 3A). We also tested 
the effect of Mcl-1 overexpression on apoptosis induced 
by vemurafenib. There was about 4-fold induction of 
apoptosis when A375 and SK-MEL-28 cells were treated 
with vemurafenib (Fig. 3B). Upon Mcl-1 overexpression, 
the apoptosis induced by vemurafenib was completely 
abrogated (Fig. 3B). These results were further supported 
by our western blot results. Upon vemurafenib treatment, 
there was a marked cleavage of caspase 3 and PARP in 
both the cell lines, which was completely diminished upon 
Mcl-1 overexpression (Figs. 3C–3D).
To further establish a connection between Mcl-1 
and vemurafenib resistance, we generated A375-Mcl-1+/+ 
and SK-MEL-28-Mcl-1+/+ cell lines exhibiting stable 
overexpression of Mcl-1, and then evaluated the effect of 
vemurafenib in these cell lines. As expected, these cells 
behaved very similar to the resistant cells when treated 
with vemurafenib. The survival of A375-Mcl-1+/+ cells 
was reduced by only 20% and 25% when treated with 
0.2 μM and 0.4 μM vemurafenib respectively (Fig. 3E). 
In SK-MEL-28-Mcl-1+/+ cells, no change was observed 
when treated with 0.2 μM vemurafenib but about 15% 
reduction in cell survival was observed when treated 
with 0.4 μM vemurafenib (Fig. 3E). In contrast, both 
the respective wild type (parent) cell lines were highly 
sensitive to vemurafenib treatment (Fig. 3E). Vemurafenib 
treatment was able to induce a modest 2 fold increase in 
apoptosis in both the melanoma cell lines with stable 
Mcl-1 overexpression in contrast to 6 fold induction of 
apoptosis in the respective parent cell lines (Fig. 3F). 
These results established the involvement of Mcl-1 in 
the induction of acquired resistance to vemurafenib in 
melanoma cells.
Silencing Mcl-1 reverses vemurafenib resistance
To examine whether silencing Mcl-1 could 
overcome vemurafenib resistance in melanoma cells, 
Mcl-1 was silenced using two different siRNAs, which 
were denoted as siRNA#1 and siRNA#2. The sequences 
of siRNAs are given in Supplemental Table 1. We first 
tested the effect of Mcl-1 silencing in A375-Mcl-1+/+ 
and SK-MEL-28-Mcl-1+/+ cells, since the response of 
these cells to vemurafenib was analogous to the resistant 
cell lines (A375-VR and SK-MEL-28-VR). Almost 
100% silencing of Mcl-1 was achieved with both the 
siRNAs in both the Mcl-1 overexpressing cell lines 
(Fig. 4C). As mentioned above, vemurafenib treatment 
had very minimal effect on A375-Mcl-1+/+ cells whereas 
SK-MEL-28-Mcl-1+/+ cells were completely resistant 
(Fig. 4A). However, upon silencing of Mcl-1by siRNA#1 
or siRNA#2, vemurafenib suppressed the survival of 
A375-Mcl-1+/+ cells by 73% and that of SK-MEL-28-
Mcl-1+/+ cells by 70% (Fig. 4A). Likewise, combination 
of vemurafenib with Mcl-1 siRNA#1 and Mcl-1 siRNA#2 
induced 5 fold apoptosis in both the Mcl-1 overexpressing 
cell lines (Fig. 4B). These observations were further 
supported by our western blot results. With vemurafenib 
treatment, there was no change in the cleavage of caspase 
3 and PARP as compared to control in both the Mcl-1 +/+ 
cell lines (Fig. 4C). However, when Mcl-1 was silenced 
and the cells were treated with vemurafenib, significant 
apoptosis was induced as depicted by cleavage of caspase 
3 and PARP (Fig. 4C).
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Figure 3: Mcl-1 overexpression reduces the sensitivity of melanoma cells to vemurafenib. A–B. A375 and SK-MEL-28 
untransfected or transfected with Mcl-1 plasmid were treated with 0.2 μM and 0.4 μM vemurafenib for 72 hours. The cell survival was 
evaluated by sulforhodamine B assay and apoptosis was evaluated by Annexin V/FITC assay. The experiment was performed at least 
three times independently, each time with four replicates and the data is expressed as mean ± S.D. *p < 0.05 when compared with control. 
In a similar experiment, C. A375 and D. SK-MEL-28 cells untransfected or transfected with Mcl-1 plasmid were treated with 0.4 μM 
vemurafenib for 72 hours. Following the treatment, the lysates were subjected to western blotting and analyzed for Mcl-1, cleaved caspase 
3 and cleaved PARP. β actin was used as a loading control. Each experiment was performed at least three times independently. E. A375 
and A375-Mcl-1+/+ or SK-MEL-28 and SK-MEL-28-Mcl-1+/+ were treated with 0.2 μM and 0.4 μM vemurafenib for 72 hours and cell 
survival was evaluated. F. A375 and A375-Mcl-1+/+ or SK-MEL-28 and SK-MEL-28-Mcl-1+/+ were treated with 0.4 μM vemurafenib for 
72 hours and apoptosis was evaluated. The experiment was performed at least three times independently, each time with four replicates and 
the data is expressed as mean ± S.D. *p < 0.05 when compared with control.
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Next, we sought to determine the effect of 
vemurafenib in A375-VR, A375-X/R and SK-MEL-28-
VR cells after silencing Mcl-1, as these cells expressed 
very high levels of Mcl-1. About 85–95% Mcl-1 silencing 
was achieved by both the siRNAs in all the resistant cell 
lines (Fig. 4F–4G). Upon Mcl-1 silencing, there was a 
significant reduction in cell survival in all the resistant 
cell lines when treated with vemurafenib. The survival 
of A375-VR, A375-X/R and SK-MEL-28-VR cells 
when treated with vemurafenib was decreased by 65%, 
75% and 55% respectively when Mcl-1 was silenced in 
these resistant cells (Fig. 4D). Moreover, the sensitivity 
of Mcl-1 silenced resistant cells to vemurafenib was 
very similar to that of parent (sensitive) cells that 
we observed earlier (Fig. 1A–1B). Additionally, the 
combination of vemurafenib and Mcl-1 siRNA#1 or 
Mcl-1 siRNA#2 induced 5-fold apoptosis in all the 
resistant cell lines, which were initially unresponsive 
to vemurafenib treatment (Fig. 4E). These results were 
further supported by western blotting data (Fig. 4F–4G). 
Vemurafenib treatment induced very minimal cleavage of 
caspase 3 and PARP in resistant cell lines (Fig. 4F–4G). 
Nonetheless, treatment of cells with vemurafenib after 
silencing of Mcl-1 induced notable cleavage of caspase 
Figure 4: Silencing Mcl-1 reverses vemurafenib resistance. Mcl-1 was silenced by siRNA#1 or siRNA#2 in A–B. A375-Mcl-1+/+, 
SK-MEL-28-Mcl-1+/+, D–E. A375-VR, SK-MEL-28-VR and A375-X/R after which the cells were treated with 0.4 μM vemurafenib 
for 72 hours. The cell survival was evaluated by sulforhodamine B assay and apoptosis was evaluated by Annexin V/FITC assay. The 
experiment was performed at least three times independently, each time with four replicates and the data is expressed as mean ± S.D. 
*p < 0.05 when compared with control. #, p < 0.05 when compared with vemurafenib treatment. In a similar experiment, after silencing 
Mcl-1 by siRNA#1 or Mcl-1 siRNA#2, C. A375-Mcl-1+/+, SK-MEL-28-Mcl-1+/+ and 
(Continued )
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3 and PARP (Fig. 4F–4G). Furthermore, vemurafenib 
treatment did not have any effect on p-ERK1/2 but 
when combined with Mcl-1 siRNA, phosphorylation of 
ERK1/2 was significantly suppressed (Fig. 4F–4G). The 
exact mechanism by which Mcl-1 inhibition regulates 
phosphorylation of ERK1/2 in our model is not clear 
and requires further investigation. The expression of 
ERK1/2 remained unchanged by all the treatments 
(Figs. 4F–4G). These results established that inhibition of 
Mcl-1 completely overcomes the acquired resistance to 
vemurafenib in melanoma cells.
Inhibiting Mcl-1 suppresses the growth of 
melanoma tumors resistant to vemurafenib
Although it was very evident from our in vitro 
results that inhibition of Mcl-1 completely reversed the 
acquired resistance to vemurafenib in melanoma cells, it 
was of utmost importance to translate these observations 
in vivo. At day 30, the average tumor volume of the 
control group was 1613.5 ± 231.9 mm3 while that of 
vemurafenib treated group was 1688 ± 156.19 mm3 
(Fig. 5A and 6A) indicating that the tumors did not 
respond to vemurafenib treatment at all. The tumor 
volume of the mice that were treated with TW-37 alone 
was 870 ± 187.8 mm3 demonstrating a 48% and 46% 
reduction in tumor growths as compared to the tumor 
volumes of the mice from control as well as vemurafenib 
treated group, respectively (Fig. 5A). Most importantly, 
mice that were treated with a combination of vemurafenib 
and TW-37 had significantly lower tumor volumes as 
compared to all the three groups (Fig. 5A). The average 
tumor volumes of these mice at the end of the experiment 
were 215.3 ± 51.6 mm3, showing a marked reduction in 
tumor growth by more than 85% as compared to control 
or vemurafenib treated group (Fig. 5A). In fact, the 
tumors did not grow much once the treatment started.
The average tumor volume of the mice that 
were treated with Mcl-1 siRNA alone at the end of the 
experiment was 875 ± 134.3 mm3, which was significantly 
lower than that of control and vemurafenib treated mice 
(Fig. 6A). The average tumor volume of the mice treated 
with scrambled siRNA was 1553 ± 650 mm3, showing 
no significant difference between the average volumes 
of the tumor of the mice treated with scrambled siRNA, 
vemurafenib or control mice (Fig. 6A). However, the 
average volume of the tumors in the mice that were treated 
with vemurafenib and Mcl-1 siRNA was 292 ± 48.12 mm3, 
Figure 4: (Continued ) F–G. A375-VR, SK-MEL-28-VR and A375-X/R cell lysates were prepared and the protein was subject to 
western blotting and analyzed for Mcl-1, p-ERK1/2, ERK1/2, cleaved caspase 3 and cleaved PARP. Each experiment was performed at least 
three times independently. β actin was used as a loading control.
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Figure 5: Inhibiting Mcl-1 suppresses the growth of melanoma tumors resistant to vemurafenib. A. A375-VR cells were 
injected subcutaneously in female athymic nude mice. Once the tumor volume reached 150 mm3, mice were randomly divided into 4 groups 
(n = 7 in each group) and the treatment was started as described under ‘Material and Method’ section. Group 1 mice treated with vehicle 
served as control, group 2 mice were treated with vemurafenib, group3 mice were treated with TW-37 and group 4 mice were treated with 
a combination of vemurafenib and TW-37. Tumor volumes were measure thrice a week by vernier calipers and the values were plotted as 
Mean ± S.E.M. B. At day 30, mice were sacrificed, tumors were extracted and weighed. The values are plotted as mean ± S.D. *p < 0.05 
as compared to control. #, p < 0.05 as compared to vemurafenib treated group. $, p < 0.05 as compared to TW-37 treated group. C. Tumor 
lysates from 6 mice were subjected to western blotting and analyzed for Mcl-1, p-ERK1/2, ERK, cleaved caspase 3 and cleaved PARP. 
β actin was used as loading control. D. Formalin fixed paraffin embedded tumor sections were subjected to immunohistochemistry and 
TUNEL assay. Representative images of the tumor sections stained with TUNEL, Mcl-1, p-ERK1/2 and cleaved caspase 3.
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Figure 6: Silencing Mcl-1 suppresses the growth of melanoma tumors resistant to vemurafenib. A. A375-VR cells were 
injected subcutaneously in female athymic nude mice. Once the tumor volume reach 150 mm3, the mice were randomly divided into 
5 groups (n = 6 in each group) and the treatment was started as described under ‘Material and Method’ section. Tumor volumes were 
measure thrice a week by vernier calipers and the values were plotted as Mean ± S.E.M. B. At day 30, mice were sacrificed, tumors were 
extracted and weighed. The values are plotted as mean ± S.D. *p < 0.05 as compared to control. #, p < 0.05 as compared to vemurafenib 
treated group. $, p < 0.05 as compared to TW-37 treated group. C. Tumor lysates from 6 mice were subjected to western blotting and 
analyzed for Mcl-1, p-ERK1/2, ERK1/2, cleaved caspase 3 and cleaved PARP. β actin was used as a loading control. D. Formalin fixed 
paraffin embedded tumor sections were subjected to immunohistochemistry and TUNEL assay. Representative images of the tumor sections 
stained with TUNEL, Mcl-1, p-ERK1/2 and cleaved caspase 3.
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showing a notable suppression of tumor growth by more 
than 80%, as compared to control or vemurafenib treated 
group (Fig. 6A).
At day 30, mice from all the groups were sacrificed 
and the tumors were removed and weighed. As shown in 
Fig. 5B, there was no difference in the tumor weight of 
control and vemurafenib treated mice. The weight of the 
tumor in TW-37 treated group was reduced by 47% as 
compared to control and 48% as compared to vemurafenib 
treated group (Fig. 5B). Notably, the tumor weight in the 
mice treated with TW-37 and vemurafenib was reduced 
by more than 85%, consistent with tumor volume data. 
The weight of the tumor in Mcl-1 siRNA treated group 
was reduced by 40% as compared to control and 43% 
as compared to vemurafenib treated group (Fig. 6B). 
Moreover, the tumor weight in the mice treated with 
Mcl-1 siRNA and vemurafenib was reduced by more 
than 85%, consistent with tumor volume data (Fig. 6B). 
These results clearly indicated that Mcl-1 overexpression 
led to vemurafenib resistance and that inhibition of 
Mcl-1 sensitized the vemurafenib resistant tumors to 
vemurafenib.
Vemurafenib resistant tumors exhibit 
overexpression of Mcl-1
Upon termination of in vivo experiments, 
tumors were examined by western blotting and 
immunohistochemistry. The control tumors showed marked 
expression of Mcl-1 (Fig. 5 and 6C–6D). Interestingly, 
tumors from vemurafenib treated group had even higher 
expression of Mcl-1 than the tumors from control group 
(Fig. 5 and 6C–6D). The tumors from the mice that were 
treated with either Mcl-1 inhibitor (Fig. 5C–5D) or Mcl-1 
siRNA alone (Fig. 6C–6D) had diminished expression 
of Mcl-1. Nonetheless, the tumors from the mice that 
were treated with a combination of vemurafenib with 
either Mcl-1 inhibitor or Mcl-1 siRNA had significantly 
lower expression of Mcl-1 as compared to the tumors 
from control or vemurafenib treated group (Fig. 5C–5D). 
We also examined the expression of cleaved caspase 3, 
cleaved PARP and p-ERK1/2 in these tumors. Tumors 
from control and vemurafenib group showed minimal 
cleavage of caspase 3 or PARP (Fig. 5 and 6C–6D). 
The tumors treated with Mcl-1 inhibitor or Mcl-1 
siRNA showed modest cleavage of caspase 3 and PARP 
(Fig. 5 and 6C–6D). However, the tumors that were 
treated with the combination of vemurafenib with Mcl-1 
inhibitor or Mcl-1 siRNA showed massive cleavage 
of caspase3 and PARP. Expression of p-ERK1/2 was 
evaluated to check the inhibition of MAPK pathway. 
In control and vemurafenib treated group, where there 
was high expression of Mcl-1, we also observed notable 
phosphorylation of ERK1/2 (Fig. 5 and 6C–6D). Treatment 
with Mcl-1 inhibitor or Mcl-1 siRNA had minimal effect 
on p-ERK1/2 expression (Fig. 5 and 6C–6D). However, 
upon combining vemurafenib with either Mcl-1 inhibitor 
or Mcl-1 siRNA, there was a substantial decrease in 
the phosphorylation of ERK1/2, hence, indicating the 
inhibition of MAPK pathway (Fig. 5 and 6C–6D). 
Nevertheless, the expression of ERK1/2 was not changed 
by any of the treatments (Fig. 5C and 6C). Finally, TUNEL 
staining exhibited significant staining in the tumors of the 
mice that were treated with a combination of vemurafenib 
and Mcl-1 inhibitor/siRNA, indicating apoptosis (Fig. 5D 
and 6D). Tumors from the mice treated with vemurafenib 
showed negligible or no TUNEL staining, which was 
similar to the tumors from control mice (Fig. 5D and 6D).
Dabrafenib induces Mcl-1 expression in 
melanoma cells
While we were working with vemurafenib, 
dabrafenib, another BRAF inhibitor was approved for the 
treatment of BRAF mutant melanoma. Hence, we wanted 
to see whether the role of Mcl-1 in drug resistance was 
specific to vemurafenib or applicable to other BRAF 
inhibitors as well. We treated A375, SK-MEL-28, 
WM239 and SK-MEL-5 cells with 2.5, 5 and 10 nM 
dabrafenib for 72 hours. Similar to vemurafenib, we 
observed that dabrafenib treatment also induced massive 
Mcl-1 expression at all the three concentrations (Fig. 7A). 
We then generated dabrafenib resistant A375, SK-MEL-28 
and WM-239 cells, which were denoted as A375-DR, 
SK-MEL-28-DR and WM-239-DR. The IC50 of dabrafenib 
in A375, SK-MEL-28 and WM-239 was 5nM, 2nM and 
6nM respectively, and that of A375-DR, SK-MEL-28-
DR and WM-239-DR was greater than 100 nM indicating 
more than 30-fold resistance (Fig. 7B). As expected, 
dabrafenib resistant melanoma cells showed marked 
upregulation of Mcl-1 as compared to the respective wild 
type (sensitive) cells (Fig. 7C). The fold-increase in Mcl-1 
expression in A375-DR, SK-MEL-28-DR and WM-239-
DR was 14.2, 19.4 and 12.9 respectively (Fig. 7C).
Dabrafenib-Trametinib combination induces 
Mcl-1 expression in melanoma cells
Early 2014, FDA approved a combination of BRAF 
inhibitor (dabrafenib) and MEK1/2 inhibitor (trametinib) 
for the treatment of late stage malignant melanoma, due 
to ineffectiveness of vemurafenib monotherapy. Hence, 
we wanted to know whether the role of Mcl-1 in drug 
resistance was specific to BRAF inhibitors or applicable to 
the combination of BRAF and MEK1/2 inhibitors as well. 
We treated the cells with BRAF inhibitors (dabrafenib or 
vemurafenib) and MEK 1/2 inhibitor (trametinib) alone 
as well as in combination. As observed earlier, dabrafenib 
at a concentration of 10 nM significantly induced the 
expression of Mcl-1 in A375, SK-MEL-28, SK-MEL-5 
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and WM-239 cells (Fig. 8A). Notably, trametinib treatment 
also induced Mcl-1 expression in all the melanoma cell 
lines tested (Fig. 8A–8B). Finally, treatment of melanoma 
cells with a combination of vemurafenib or dabrafenib 
with trametinib also caused remarkable induction of Mcl-
1 which was more as compared to individual treatments 
(Fig. 8A–8B). Induction of Mcl-1 by treatment with a 
combination of dabrafenib and trametinib was investigated 
in a panel of ten BRAF mutant cell lines. Treatment of 
these cells with the combination of dabrafenib and 
trametinib induced significant expression of Mcl-1 in all 
the cell lines (Supp. Fig. 2). The fold increase in Mcl-1 
expression in response to combination treatment in each 
cell line is shown in Fig. 8C. These results indicated that 
BRAF inhibitors alone as well as in combination with 
MEK1/2 inhibitors induce Mcl-1 expression.
Mcl-1 overexpressing melanoma cells are 
resistant to combined BRAF inhibitor and 
MEK1/2 inhibitor treatment
Based on our results in Fig. 7 and 8A, we 
hypothesized that induction of Mcl-1 induces resistance 
to the combination treatment of dabrafenib and trametinib 
Figure 7: Dabrafenib induces Mcl-1 expression in melanoma cells. A. A375, SK-MEL-28, SK-MEL-5 and WM-239 were 
treated with 5–10 nM dabrafenib for 72 hours. Following the treatment, Mcl-1 expression was analyzed by western blotting. B. Cytotoxicity 
of dabrafenib at 72 hours in wildtype and dabrafenib resistant A375-DR, SK-MEL-28-DR and WM-239-DR was evaluated by SRB assay. 
C. The expression of Mcl-1 in A375, SK-MEL-28 and WM-239 wild type cells and dabrafenib resistant cells was evaluated by western 
blotting. β actin was used as a loading control in all the western blot experiments. Each experiment was performed at least three times 
independently.
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in melanoma cells. In order to test our hypothesis and 
to characterize the role of Mcl-1 in resistance to the 
combination treatment of BRAF inhibitor with MEK1/2 
inhibitor, we evaluated the effect of Mcl-1 overexpression 
on the efficacy of these therapeutic regimens. Our results 
showed that Mcl-1 overexpression not only reduced the 
efficacy of either BRAF inhibitor or MEK1/2 inhibitor 
alone but also their combination (Fig. 9A–9D). For 
example, dabrafenib, trametinib or the combination 
reduced the survival of A375 and SK-MEL-28 cells by 60–
70% (Fig. 9A–9B). However, upon Mcl-1 overexpression, 
the reduction in cell survival with any of the treatments 
was at the most 25% (Fig. 9A–9B). In SK-MEL-28, 
Mcl-1 overexpression completely blocked the effect of 
Figure 8: Dabrafenib-Trametinib combination induces Mcl-1 expression in melanoma cells causing drug 
resistance. A375, SK-MEL-28, SK-MEL-5 and WM-239 were treated A. 10 nM dabrafenib and 2nM trametinib and B. 0.4 μM 
vemurafenib and trametinib for 72 hours. Following the treatment, Mcl-1 expression was analyzed by western blotting. β actin was used as a 
loading control in all the western blot experiments. C. Ten mutant BRAF melanoma cell lines were treated with a combination of dabrafenib 
(10nM) and trametinib (2 nM) for 72 hours. The protein was collected, subjected to western blotting and analyzed for Mcl-1 expression. 
Fold increase in Mcl-1 expression was calculated by densitometric analysis. Actin was used as a loading control. Each experiment was 
performed at least three times independently.
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dabrafenib (Fig. 9B). Similar results were observed when 
Mcl-1 overexpressing melanoma cells were treated with a 
combination of vemurafenib and trametinib (Fig. 9C–9D).
Tumor biopsy samples exhibit enhanced Mcl-
1 expression in patients treated with BRAF 
inhibitors alone or in combination with MEK1/2 
inhibitors
Next, we wanted to confirm our hypothesis by 
examining clinical specimens. The exact treatment 
regimen along with the response of patient to treatment 
is given in Table 1. Mcl-1 expression was evaluated in 
the biopsied tumor samples by immunohistochemistry. 
Our results showed that tumors that were biopsied from 
the patients treated with BRAF inhibitors had significantly 
higher expression of Mcl-1 as compared to the tumors 
from the same patient before any treatment (Fig. 10A). 
Since the patients initially responded to the treatment, 
some of the biopsy samples had very few tumor cells. 
However, tumor cells that survived the treatment exhibited 
overexpression of Mcl-1 (Fig. 10A). Moreover, the tumor 
samples from patients (9, 13, 25, and 29) which received 
both dabrafenib and trametinib also demonstrated elevated 
Figure 9: Mcl-1 overexpression reduces the sensitivity of melanoma cells to BRAF inhibitor and MEK inhibitor 
combination treatment. A. A375 and B. SK-MEL-28 untransfected or transfected with Mcl-1 plasmid were treated with 10 nM 
dabrafenib or 2 nM trametinib for 72 hours. C. A375 and D. SK-MEL 28 cells untransfected or transfected with Mcl-1 plasmid were treated 
with 0.4 μM vemurafenib or 2 nM trametinib for 72 hours. The cell survival was evaluated by sulforhodamine B assay. The experiment 
was performed at least three times independently, each time with four replicates and the data is expressed as mean ± S.D. *p < 0.05 when 
compared with control. #, p < 0.05 when compared to respective cells transfected with empty vector. Each experiment was performed at 
least three times independently.
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expression of Mcl-1 (Fig. 10A). Furthermore, progression 
biopsy revealed enhanced expression of Mcl-1 as 
compared to the pretreated tumors from the same patient 
(Fig. 10B). Hence, these results showed that treatment 
with BRAF inhibitor alone or in combination with 
MEK1/2 inhibitor caused Mcl-1 overexpression, which 
correlated with relative resistance.
DISCUSSION
All the melanoma cell lines tested in the present 
study were highly sensitive to the treatment with BRAF 
inhibitors (vemurafenib and dabrafenib) alone or in 
combination with MEK1/2 inhibitor (trametinib). In spite 
of this, it was surprising to see a significant upregulation 
of Mcl-1 in the surviving cells following a single 
treatment with BRAF inhibitors. Our previous study did 
not observe any significant change in the expression of 
Mcl-1 with BRAF inhibitor treatment [26]. However, the 
expression of Mcl-1 in aforementioned study was tested 
only after 24 hours of treatment in contrast to 72 hours 
treatment in the current study. This suggests that Mcl-1 
expression was induced upon longer duration of treatment. 
Moreover, the dead floating cells which responded to 
vemurafenib treatment had diminished Mcl-1 expression, 
consistent with previous reports indicating that inhibition 
of oncogenic BRAF led to inhibition of Mcl-1 [27–29]. 
Subsequently, in the current study, the cells resistant to 
BRAF inhibitors exhibited enhanced expression of Mcl-1. 
This provided initial evidence that overexpression of Mcl-
1 might be responsible for acquired resistance to BRAF 
inhibitors in melanoma cells.
Induction of Mcl-1 with the treatment with BRAF 
inhibitors may indicate activation of other pathways post 
treatment leading to upregulation of Mcl-1. Expression 
of Mcl-1 is promoted by various transcription factors 
like STATs, cAMP response elements and NFκB [16]. 
Recent studies have correlated the activation of Src and 
STAT-3 with vemurafenib resistance [30, 31]. Both these 
pathways can directly or indirectly stimulate Mcl-1 
expression. Moreover, activation of other unknown 
pathways may also cause induction of Mcl-1 expression. 
Nonetheless, targeting upstream molecules may provide 
little benefit to overcome vemurafenib resistance as 
compared to targeting Mcl-1 directly, as Mcl-1 is the 
ultimate downstream molecule and directly responsible 
for causing resistance to BRAF inhibitors. Additionally, 
targeting upstream molecules for therapy often fails as the 
intermediary molecules often get mutated or influenced 
by cross talk with other survival pathways resulting in the 
ineffectiveness of therapy [32–34].
Our studies provided several in vitro and in vivo 
evidences to prove this and established Mcl-1 as the 
major culprit in inducing resistance to BRAF inhibitors in 
melanoma. Wild type A375 and SK-MEL-28 melanoma 
cells completely lost sensitivity to BRAF inhibitors alone 
or in combination with MEK1/2 inhibitors upon Mcl-1 
overexpression and transformed them into resistant cells.
The involvement of Mcl-1 in resistance to BRAF 
inhibitors was strengthened when vemurafenib resistant 
A375-VR or SK-MEL-28-VR cells were treated with the 
combination of vemurafenib with TW-37 (Mcl-1 inhibitor) 
or Mcl-1 siRNAs, and the combination treatment markedly 
induced apoptosis in both the cell lines which were 
earlier resistant to vemurafenib treatment. Moreover, the 
combination of vemurafenib with TW-37 or Mcl-1 siRNA 
dramatically inhibited the growth of A375-VR tumors, 
which exhibited complete resistance to vemurafenib 
treatment. Surprisingly, even though TW-37 or Mcl-1 
siRNA did not have any effect on the phosphorylation 
of ERK1/2, their combination with vemurafenib led to 
Table 1: Patient samples
Patient ID RX Response (RECIST) Time to Progression (months)
9 dabrafenib + trametinib PR (−45%) 7
13 dabrafenib + trametinib PR (−57.9%) 9,stroke
35 LGX818 + MEK162 SD (−22.8%) stopped after 7 months,PD at 10 months
43 BRAFi + IL2 CR (−81.5%) 13.4
20 vemurafenib PR (−51.2%) 5
28 vemurafenib SD 22
29 dabrafenib + trametinib PR (−79%) 9
PPP BRAFi + IL2 PR (−72.6%) Ongoing
25 dabrafenib + trametinib PR (−64%) 3
Patients with metastatic melanoma containing BRAFV600Emutation (confirmed by genotyping) were enrolled on clinical 
trials for treatment with a BRAF inhibitor (vemurafenib) or combined BRAF + MEK inhibitor (dabrafenib + trametinib). 
Listed are patient ID, treatment, maximum response (RECIST), time to progression (months).
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Figure 10: Tumor biopsy samples exhibited enhanced Mcl-1 expression in patients treated with BRAF inhibitor alone 
or in combination with MEK1/2 inhibitor. Immunohistochemistry was performed to analyze Mcl-1 in tumor biopsy samples from 
patients A. before the treatment with BRAF inhibitor or combination and on BRAF inhibitor and B. before the treatment followed by 
progression biopsy. The patients were treated with either BRAF inhibitors (vemurafenib, dabrafenib, LGX818) alone or in combination 
with BRAF inhibitors (trametinib, MEK162). The representative positive cells are shown by the arrow.
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decrease in the levels of p-ERK1/2. This may indicate 
that in presence of Mcl-1 inhibitor, vemurafenib was 
effectively controlling the MAPK pathway. However, the 
exact mechanism by which phosphorylation of ERK1/2 
was suppressed require further investigation.
TW-37 is a BH-3 mimetic which binds to Mcl-
1 and Bcl-2 with a Ki of 260 and 290 nM respectively 
and consequently induces caspase activity. TW-37 binds 
to Bcl-XL with a 5 fold lower affinity (Ki≈1200 nM) 
[35, 36]. Therefore, in order to inhibit Bcl-XL, cells should 
be treated with at least 5 fold higher concentration of TW-
37 as compared to that used in the current study, sufficient 
to inhibit Mcl-1 but not Bcl-XL [37]. We observed that 
treatment of melanoma cells with BRAF inhibitors did 
not induce Bcl-2 expression. Moreover, there was no 
difference in the expression of Bcl-2 between the wild type 
and resistant melanoma cells. Besides, previous studies 
have shown reduced expression of Bcl-2 in melanoma as 
compared to melanocytes and benign nevi [38–42], ruling 
out the involvement of Bcl-2 in our study. Furthermore, the 
concentrations of TW-37 used for this study were not able 
to inhibit the expression of Bcl-XL in vivo (Supplemental 
Fig. 3). These factors somewhat eliminated the involvement 
of other antiapoptotic Bcl-2 family of proteins. More 
importantly, the in vitro and in vivo observations were 
confirmed by using Mcl-1 siRNA along with vemurafenib 
treatment, which further ruled out the involvement of other 
antiapoptotic Bcl-2 family proteins. In fact, two Mcl-1 
siRNAs with different sequences were used to ensure target 
specificity and to eliminate off-target actions.
Finally, highly elevated expression of Mcl-1 
in the biopsy samples obtained from the patients that 
were treated with or resistant to BRAF inhibitors like 
vemurafenib or dabrafenib alone or in combination with 
MEK1/2 inhibitor (trametinib) further confirmed that 
Mcl-1 may be responsible for induction of resistance to 
the entire class of BRAF inhibitors.
The translational consequences of these findings 
are significant. Our results conclusively establish that 
overexpression of Mcl-1 is critical for melanoma cell 
survival in the setting of BRAF inhibitor treatment and 
induce clinical resistance to BRAF inhibitors. To date, 
Mcl-1 targeted therapies have not been well established in 
the clinic, however based on this work and others, Mcl-1 
is an obviously high valued target in oncology. Instead, 
the major so-called BH3-mimetics that are in clinical 
trials are those that inhibit Bcl-2 quite selectively (ABT-
199) or more broadly (navitoclax, ABT-737), though even 
navitoclax only selectively inhibits Bcl-2, Bcl-x, Bcl-w 
and does not have any activity against Mcl-1. Due to the 
exciting preclinical data with Bcl2/Bcl-x inhibitors in 
combination with single-agent BRAF inhibitors [26, 43], 
combined BRAF targeted therapy with navitoclax as part 
of a CTEP study (P9466, NCT01989585) has commenced. 
Still, the prediction from our current and previous work 
is that patients with high Mcl-1 expression exists, either 
at baseline or by BRAF inhibitors, and these patients will 
be less likely to benefit from such a combination. Next 
important step is to develop clinical assay to measure 
Mcl-1 expression, so that patients likely to benefit from 
non-Mcl-1 targeting BH3 mimetics could be identified, 
ideally prior to therapy or early after the commencement 
of therapy. Beyond that, as the clinical development of 
Mcl-1 inhibitors proceed, an early look at combinations 
with BRAF targeted therapy will be critical.
Taken together, our results conclusively established 
that overexpression of Mcl-1 was responsible for the 
resistance to BRAF inhibitors; the process mediated by 
BRAF inhibitors itself. Mcl-1 targeted therapies will have 
significant impact on the patients with melanoma tumors 
refractory to BRAF inhibitors alone or in combination 
with MEK1/2 inhibitor. Although, currently there is no 
FDA approved Mcl-1 inhibitor, the process to discover 
clinically useful Mcl-1 inhibitors has well begun [24, 25, 
44, 45]. Our laboratory is also aggressively working on 
developing novel Mcl-1 inhibitors as drugs.
MATERIAL AND METHODS
Chemicals
Vemurafenib, dabrafenib, trametinib and TW-37 
were purchased from Selleck Chemicals (Houston, YX, 
USA). Mcl-1 antibody was purchased from Abcam 
(Cambridge, MA, USA). All the antibodies and Mcl-1 
siRNAs were procured from Cell Signaling Technology 
Inc. (Danvers, MA, USA). Plasmid overexpressing Mcl-1 
was acquired from Addgene (Cambridge, MA, USA). 
TUNEL assay kit was purchased from Calbiochem (San 
Diego, CA, USA)
Cell culture
A375 was a kind gift from Dr. Tyler Wakenda 
(Rochester University, NY), which was originally 
purchased from ATCC (Manassas, VA, USA). 
SK-MEL-28 and WM-239 cells were purchased from 
ATCC. SK-MEL-5 was a kind gift from Dr. Randy Burd. 
The authenticity of these cell lines was confirmed by STR 
analysis at Texas Tech University Health Sciences Center 
core facility (Lubbock, TX, USA). All the cell lines were 
cultured in Eagle’s Minimum Essential Medium (EMEM) 
supplemented with 10% fetal bovine serum. MEL624, 
MEL526, UACC903, UACC257, C32 and A2058 were 
grown in DMEM medium supplemented with 10% FBS 
and 1% penicillin/streptomycin and 2 mM L-glutamine, 
and maintained at 37°C in a humidified atmosphere at 5% 
CO2. These cell lines were obtained from cryopreserved 
collections at Massachusetts General Hospital, courtesy 
of H.Tsao.
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Generation of BRAF-inhibitor resistant cell lines
Vemurafenib resistant clones of A375 and SK-
MEL-28 were generated by continuous exposure of cells 
to escalating concentrations of vemurafenib over a period 
of one year. The cells were treated with vemurafenib for 
72 hours after which fresh media was added to the cells. 
The cells were allowed to recover for 24 hours after 
which they were again exposed to vemurafenib as shown 
in Supp. Tables 2–3. In all, cells were exposed weekly to 
two treatments of vemurafenib for 72 hours each with a 
24 hour recovery period between the treatments. The 
initial concentration of vemurafenib used was 0.2 μM 
which was eventually increased to as high as 10 μM. 
Similarly, dabrafenib resistant cells were cultured by 
incubating the cells with increasing concentrations of the 
drug for a period of 3 months as described above. The fold 
resistance was intermittently evaluated by cell viability 
assay. Vemurafenib resistant cell lines were referred to 
as SK-MEL-28-VR or A375-VR and dabrafenib resistant 
cell lines were referred to as A375-DR, SK-MEL-28-DR 
or WM-239-DR. Another resistant cell line was generated 
from A375 xenograft-resistant (A375 X/R) tumors. Here, 
A375-VR cells were injected subcutaneously in nude 
mice. When palpable tumors were formed, the mice 
were orally treated with 30 mg/kg vemurafenib twice a 
day. After 30 days of treatment, cells from the tumors of 
mice treated with vemurafenib were isolated and cultured 
in vitro. These cells were named as A375 X/R cells.
Cytotoxicity analysis
SK-MEL-28, A375, WM-239, SK-MEL-28-VR, 
A375-VR, A375-X/R, A375-DR, SK-MEL-28-DR and 
WM-239-DR cells were treated with various concentrations 
of vemurafenib or dabrafenib and cytotoxicity was 
performed by SRB assay as previously described by us 
[46, 47].
Apoptosis assay
Annexin V/FITC assay was perform by flow 
cytometry after TW-37 treatments, Mcl-1 overexpression 
or Mcl-1 silencing according to manufacturer’s protocol 
(BD Biosciences, San Diego, CA, USA) as previously 
described by us [48].
TW-37 treatment
SK-MEL-28, A375, SK-MEL-28-VR, A375-VR 
and A375-X/R were plated in a six-well plate at a density 
of 0.3 × 106 cells/well and left overnight to attach. Next 
day, cells were treated with 500nM TW-37 for one hour 
followed by treatment with 0.4 μM vemurafenib for 
72 hours. Cells were collected and processed for SRB 
assay, apoptosis assay or western blotting.
Mcl-1 overexpression
A375 or SK-MEL-28 cells were transiently or 
stably transfected with plasmid overexpressing Mcl-1 by 
nucleofection kit (Lonza, Basel, Switzerland) according 
to manufacturer’s protocol and previously described by us 
[49]. Briefly, 2 × 106 cells were suspended in a reaction 
mixture from the kit specific to the cell line (Kit V for 
A375 and Kit R for SK-MEL-28 cells). The cells were 
transferred to the cuvettes and electroporated using the 
nucleofector instrument (Amaxa, Cologne, Germany). 
To achieve stable overexpression, after transfection, cells 
were exposed to puromycin with an initial concentration 
of 1 μg/ml, which was gradually increased to 5 μg/ml. The 
resistant colonies were picked by colony picking cylinder 
and were cultured in presence of puromycin (5 μg/ml). 
Stable overexpression of Mcl-1 was intermittently tested 
by western blotting. A375 or SK-MEL-28 cells with stable 
overexpression of Mcl-1 were denoted as A375-Mcl-1+/+ 
or SK-MEL-28-Mcl-1+/+ respectively.
Mcl-1 silencing
Silencing of Mcl-1 was achieved according to the 
protocol described by us previously [50]. Briefly, 0.3 × 106 
cells were plated in OPTI-MEM without antibiotics and 
transfected with Mcl-1 siRNA#1, Mcl-1 siRNA#2 or 
scrambled siRNA. Complexes were prepared by incubating 
10nM siRNA with 8 μl siPORT transfection reagent in 
200 μl OPTI-MEM media without serum or antibiotic for 
20 minutes. These complexes were then added to the cells. 
Six hours after transfection, complexes were replaced with 
fresh medium.
Tumor therapy
All the experiments involving animals were approved 
by the Institutional Animal Care and Use Committee. 
About 5–6 weeks old athymic nude mice (Charles River, 
Wilmington, MA, USA) were allowed to acclimatize for 
one week prior to the beginning of the experiments. Mice 
were injected subcutaneously with 3.5 × 106 A375-VR cells. 
When the tumor volume reached to 150 mm3, mice were 
randomly segregated into several groups with 6–7 mice in 
each group. Vemurafenib, formulated as microprecipitated 
bulk powder (MBP) was suspended at a desired 
concentration in a vehicle containing 2% Klucel LF and 
adjusted to pH 4 with HCl, was given at a dose of 25 mg/
kg twice a day through oral gavage. TW-37 in PBS/ethanol/
Tween 80 was administered intraperitonially at a dose of 30 
mg/kg thrice a week. Mcl-1 (0.2 nmol) or scrambled siRNA 
was administered twice a week directly into the tumors 
(intra-tumoral injection) as described by us previously [50]. 
Tumor measurements were taken thrice a week by vernier 
calipers and the volume was calculated by the formula 
V = length * (breadth)2/2 as previously described [51–53]. 
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At the end of the experiment, animals were euthanized 
humanely and tumors were excised and fixed in formalin 
for immunohistochemistry or flash frozen in liquid nitrogen 
for western blot analysis as described previously by us [54].
Immumnohistochemistry
Immunohistochemistry was performed according to 
the protocol previously described by us [55]. Expression of 
Mcl-1, cleaved caspase 3 and p-ERK1/2 in tumor samples 
were analyzed in paraffin sections obtained from five mice 
from each group. The sections were deparaffinized and 
rehydrated using decreasing concentrations of ethanol. 
Antigen retrieval process was carried out by boiling 
the sections in citrate buffer (pH 6) for 10 minutes. 
Endogenous peroxides were quenched by incubating 
the sections in 3% hydrogen peroxide solution. Sections 
were blocked using 6% goat serum for 30 minutes after 
which they were exposed to primary antibody overnight. 
Following the incubation, the expression was detected 
using Ultravision ONE detection reagent (Thermo 
Fisher, Houston, TX) according to the manufacturer’s 
protocol. The sections were then counterstained with 
Mayer’s hematoxylin and dehydrated using increasing 
concentrations of ethanol and xylene and observed under 
the microscope (Olympus).TUNEL assay was carried out 
according to the manufacturer’s protocol.
Patient samples
Patients with metastatic melanoma containing 
BRAF V600E mutation (confirmed by genotyping) were 
consented for tissue acquisition per IRB-approved protocol 
covered under DF/HCC protocol number 11–181. Tumor 
biopsies were performed pre-treatment (day 0) 10–14 days 
after treatment initiation (on treatment) and upon evidence 
of resistance to therapy (progression). Formalin-fixed 
tissue was analyzed to confirm that viable tumor was 
present via hematoxylin and eosin (H&E) staining.
Statistical analysis
All the statistical analysis was performed using 
Prism 6.0 (Graph Pad software Inc., San Diego, CA, 
USA). In vitro data was plotted as mean ± S.D. of at least 
three independent experiments and in vivo data was plotted 
as mean ± S.E.M. Data was analyzed by Student’s t-test or 
one way ANOVA followed by Tukey’s post-hoc analysis 
for multiple comparisons. Differences were considered 
statistically significant at P < 0.05.
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